...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Psychiatry and Clinical Psychopharmacology >Comparison of long-term efficacy and safety of blonanserin treatment in individuals with first-episode and relapsed schizophrenia: a 3-year retrospective study
【24h】

Comparison of long-term efficacy and safety of blonanserin treatment in individuals with first-episode and relapsed schizophrenia: a 3-year retrospective study

机译：布洛色林治疗首发和复发性精神分裂症患者的长期疗效和安全性比较：一项为期三年的回顾性研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: The objective of this retrospective chart review study was to evaluate the long-termefficacy and tolerability of blonanserin treatment in individuals with schizophrenia.Patients and methods: We collected data from 28 (56%) antipsychotic-na?ve subjects with firstepisode (FE) schizophrenia and 22 subjects with relapsed schizophrenia treated withblonanserin. We investigated psychiatric hospitalization and medication discontinuationrates, Positive and Negative Syndrome Scale (PANSS) scores, Clinical Global Impression–Severity (CGI-S) scale scores, body mass index (BMI) at baseline to endpoint and laboratorytests including serum prolactin, total cholesterol (TC), low-density lipoproteins (LDL), highdensity lipoproteins (HDL), triglycerides (TG), and glucose. Additionally, we measured thedifferences between the two groups and overall changes in levels.Results: Thirty-one subjects received blonanserin for 3 years. Significant improvements inpsychiatric symptoms from baseline to endpoint were observed individuals withschizophrenia who received blonanserin treatment. There were remarkable changes inPANSS and CGI-S scores between baseline and those measured after 3 years (p < .01) in bothgroups; the FE schizophrenia group demonstrated better improvement as reflected byclinical changes assessments. Compared to baseline values, the endpoint measurementsshowed no statistical differences in terms of serum prolactin, glucose, or LDL and HDLcholesterol (p > .05) in both groups. After 3 years of treatment, there was a statisticallysignificant increase in TC and TG with only a minimal increase in BMI (p < .05). However,there were no statistical differences between the two groups.Conclusion: Blonanserin is useful for the maintenance treatment of schizophrenia due to itstherapeutic efficacy; moreover, it does not induce hyperprolactinaemia, significant weightgain, or cause problematic endocrine effects. Its strength might be attributed to its uniquepharmacological properties.
机译：目的：本回顾性图表审查研究的目的是评估布兰色林治疗精神分裂症患者的长期疗效和耐受性。患者和方法：我们收集了28名（56％）初发抗精神病药物的受试者的数据）精神分裂症和22名接受布兰色林治疗的精神分裂症复发患者。我们调查了精神科住院和药物停用率，阳性和阴性综合征量表（PANSS）得分，临床总体印象-严重程度（CGI-S）量表得分，基线至终点的体重指数（BMI）和实验室测试，包括血清催乳素，总胆固醇（ TC），低密度脂蛋白（LDL），高密度脂蛋白（HDL），甘油三酸酯（TG）和葡萄糖。此外，我们测量了两组之间的差异以及总体水平的变化。结果：31名受试者接受了布兰色林治疗3年。从基线到终点，精神分裂症症状得到了显着改善，观察到患有精神分裂症的个体接受了布兰色林治疗。两组之间的基线和3年后测量的PANSS和CGI-S评分均存在显着变化（p <.01）。 FE精神分裂症组表现出更好的改善，如临床变化评估所反映。与基线值相比，终点测量结果显示两组的血清催乳素，葡萄糖或LDL和HDL胆固醇均无统计学差异（P> 0.05）。经过3年的治疗，TC和TG的增加在统计学上具有显着性，而BMI仅有极小的增加（p <.05）。结论：博兰色林具有治疗精神分裂症的功效，可用于精神分裂症的维持治疗。此外，它不会诱发高催乳激素血症，显着的体重增加或引起有问题的内分泌作用。其强度可能归因于其独特的药理特性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号